IGF2BP3 and acute myeloid leukemia: IGF2BP3 loss suppresses proliferation, induces apoptosis, and impairs the leukemogenic potential of AML cells in vitro and in vivo by stabilizing m6A-modified RCC2 mRNA, which encodes a key regulator of cell cycle progression [42].